Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes

Modern Pathology

Volumn 28, Issue 3, 2015, Pages 373-382

  Zuo, Zhuang ^a   Maiti, Sourindra ^a   Hu, Shimin ^a   Loghavi, Sanam ^a   Calin, George A ^a   Garcia Manero, Guillermo ^a   Kantarjian, Hagop M ^a   Medeiros, L Jeffrey ^a   Cooper, Laurence J N ^a   Bueso Ramos, Carlos E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; FEMALE; GENE CONTROL; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; RNA EXTRACTION; WORLD HEALTH ORGANIZATION; BLOOD; CHROMOSOME ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CYTOGENETIC ANALYSIS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84938416037     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.108     Document Type: Article

References (46)

1. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088
3. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview, In: Swerdlow SH, Campo E, Harris NL, et al. (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn., IARC: Lyon; 2008, pp 88-93
4. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361
5. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820-829
6. Nybakken GE, Bagg A. The genetic basis and expanding role of molecular analysis in the diagnosis, prognosis, and therapeutic design for myelodysplastic syndromes. J Mol Diagn 2014;16:145-158
7. Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 2005;352:536-538
8. Malcovati L, Germing U, Kuendgen A, et al. Timedependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510
9. Bains A, Luthra R, Medeiros LJ, et al. FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol 2011;135: 62-69
10. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506
11. Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010; 24:756-764
12. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-2465
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297
14. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10: 704-714
15. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids-The mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8:467-477
16. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010;101: 2087-2092
17. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105: 10513-10518
18. Michael A, Bajracharya SD, Yuen PS, et al. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis 2010;16:34-38
19. Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009;15:5473-5477
20. Kosaka N, Izumi H, Sekine K, et al. microRNA as a new immune-regulatory agent in breast milk. Silence 2010;1:7
21. Zuo Z, Calin GA, de Paula HM, et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood 2011;118:413-415
22. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8:118-127
23. Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 2011;29:2240-2246
24. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008;22:538-543
25. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with colorcoded probe pairs. Nat Biotechnol 2008;26:317-325
26. Grasedieck S, Sorrentino A, Langer C, et al. Circulating microRNAs in hematological diseases: principles, challenges, and perspectives. Blood 2013;121: 4977-4984
27. Rasmussen KD, Simmini S, Abreu-Goodger C, et al. The miR-144/451 locus is required for erythroid homeostasis. J Exp Med 2010;207:1351-1358
28. Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene-and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116:3622-3626
29. Li X, Sanda T, Look AT, et al. Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. J Exp Med 2011;208:663-675
30. Ng EK, Li R, Shin VY, et al. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 2013;8:e53141
31. Vasilatou D, Papageorgiou SG, Kontsioti F, et al. Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34 bone marrow cells of patients with myelodysplastic syndromes. Leuk Res 2013;37:251-258
32. Pigati L, Yaddanapudi SC, Iyengar R, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010; 5:e13515
33. Suh SS, Yoo JY, Nuovo GJ, et al. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci USA 2012;109:5316-5321
34. Kumar M, Lu Z, Takwi AA, et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011;30:843-853
35. Lu D, Davis MP, Abreu-Goodger C, et al. MiR-25 regulates Wwp2 and Fbxw7 and promotes reprogramming of mouse fibroblast cells to iPSCs. PLoS One 2012;7:e40938
36. Okamoto K, Ishiguro T, Midorikawa Y, et al. miR-493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liver. EMBO J 2012;31:1752-1763
37. Ueno K, Hirata H, Majid S, et al. Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4. Mol Cancer Ther 2012;11:244-253
38. Laine SK, Alm JJ, Virtanen SP, et al. MicroRNAs miR-96, miR-124, and miR-199a regulate gene expression in human bone marrow-derived mesenchymal stem cells. J Cell Biochem 2012;113:2687-2695
39. Wang Y, Huang JW, Calses P, et al. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res 2012;72:4037-4046
40. Zhu W, Liu X, He J, et al. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer 2011;11:393
41. Patnaik SK, Yendamuri S, Kannisto E, et al. MicroRNA expression profiles of whole blood in lung adenocarcinoma. PLoS One 2012;7:e46045
42. Galluzzi L, Morselli E, Vitale I, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010;70:1793-1803
43. Zhou B, Ma R, Si W, et al. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett 2013;333:159-169
44. Tanaka M, Oikawa K, Takanashi M, et al. Downregulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009;4:e5532
45. Umezu T, Ohyashiki K, Kuroda M, et al. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene 2013;32:2747-2755
46. Ohyashiki JH, Umezu T, Kobayashi C, et al. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes 2010;3:347.